Literature DB >> 12422003

Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness.

K L Haywood1, A M Garratt, K Jordan, K Dziedzic, P T Dawes.   

Abstract

OBJECTIVE: To assess the acceptability and measurement properties of four ankylosing spondylitis (AS)-specific, patient-assessed measures of health outcome: AS Quality of Life Questionnaire (ASQoL), Bath AS Disease Activity Index (BASDAI), the Body Chart and the Revised Leeds Disability Questionnaire (RLDQ).
METHODS: Instruments were administered by means of a self-completed questionnaire to patients recruited from across the United Kingdom (UK). Instruments were assessed for data quality and scaling assumptions. Where appropriate, dimensionality was assessed using principle component analysis (PCA). Internal consistency reliability was tested using Cronbach's alpha. Test-retest reliability was assessed in those patients reporting no change in AS-specific health at 2 weeks. The convergent validity of the instruments was assessed and scores were correlated with responses to the health transition questions. Responsiveness was assessed for patients reporting change in health at 6 months.
RESULTS: The BASDAI and Body Chart have low self-completion rates. Item responses for the RLDQ were skewed towards higher levels of functional ability. PCA supported instrument unidimensionality. Cronbach's alpha ranged from 0.87 (BASDAI) to 0.93 (RLDQ). Test-retest reliability estimates support the use of the ASQoL and RLDQ in individual evaluation (>0.90). Correlations between instruments were in the hypothesized direction; the largest was between the ASQoL and BASDAI (0.79). The BASDAI had the strongest linear relationship, with responses to both specific and general health transition questions (P<0.01). With the exception of the Body Chart, instruments had a stronger relationship with general health transition. The BASDAI was the most responsive instrument. The Body Chart and RLDQ had low levels of responsiveness.
CONCLUSION: The instruments have undergone a comprehensive comparative evaluation to assess the measurement properties required for patient-assessed measures of health outcome. Adequate levels of reliability and validity were found for all instruments. The BASDAI and the ASQoL were the most responsive to self-perceived change in health, but the BASDAI had low levels of self-completion.

Entities:  

Mesh:

Year:  2002        PMID: 12422003     DOI: 10.1093/rheumatology/41.11.1295

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  19 in total

1.  Exploring the relation between impairment rating by DAS-28 and body function, activity participation, and environmental factors based on ICF hand core set in the patient with rheumatoid arthritis.

Authors:  Elif Gür Kabul; Ummuhan Baş Aslan; Bilge Başakçı Çalık; Murat Taşçı; Veli Çobankara
Journal:  Rheumatol Int       Date:  2018-05-30       Impact factor: 2.631

2.  Evaluating the reliability of Persian version of ankylosing spondylitis quality of life (ASQoL) questionnaire and related clinical and demographic parameters in patients with ankylosing spondylitis.

Authors:  Sasan Fallahi; Ahmad Reza Jamshidi; Katayoon Bidad; Mostafa Qorbani; Mahdi Mahmoudi
Journal:  Rheumatol Int       Date:  2013-10-30       Impact factor: 2.631

3.  Positive and negative affective states and disease activity in ankylosing spondylitis.

Authors:  Carlos Jesús Delgado Domínguez; Pilar Font Ugalde; Desireé Ruiz Vilchez; Hugo Carretero-Dios; Eduardo Collantes Estévez
Journal:  Rheumatol Int       Date:  2014-08-15       Impact factor: 2.631

4.  Greek adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQoL) measure.

Authors:  J E Graham; M Rouse; J Twiss; S P McKenna; A A Vidalis
Journal:  Hippokratia       Date:  2015 Apr-Jun       Impact factor: 0.471

5.  Patients with well-established ankylosing spondylitis show limited deterioration in a ten-year prospective cohort study.

Authors:  E L Healey; K L Haywood; K P Jordan; A M Garratt; J C Packham
Journal:  Clin Rheumatol       Date:  2012-09-27       Impact factor: 2.980

6.  Decreased physical activity and cardiorespiratory fitness in adults with ankylosing spondylitis: a cross-sectional controlled study.

Authors:  Tom O'Dwyer; Finbar O'Shea; Fiona Wilson
Journal:  Rheumatol Int       Date:  2015-08-09       Impact factor: 2.631

7.  Evaluation of internal consistency and re-test reliability of Bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan.

Authors:  James Cheng-Chung Wei; Ruey-Hong Wong; Jun-Huang Huang; Chen-Tung Yu; Chung-Tei Chou; Ming-Shiou Jan; Gregory J Tsay; Ming-Chih Chou; Hong-Shen Lee
Journal:  Clin Rheumatol       Date:  2007-02-08       Impact factor: 2.980

Review 8.  Treat-to-target in axial spondyloarthritis - what about physical function and activity?

Authors:  Jürgen Braun; Xenofon Baraliakos; Uta Kiltz
Journal:  Nat Rev Rheumatol       Date:  2021-07-26       Impact factor: 20.543

9.  The relationship between disease activity measured by the BASDAI and psychological status, stressful life events, and sleep quality in ankylosing spondylitis.

Authors:  Yutong Jiang; Mingcan Yang; Husheng Wu; Hui Song; Feng Zhan; Shengyun Liu; Guanmin Gao; Zhangsuo Liu; Zhaoxian Hu; Peigen He; Shengtao Zhang; Zaiying Hu; Zhiming Lin; Yanli Zhang; Yinong Li; Lingxun Shen; Anbing Huang; Zetao Liao; Shuangyan Cao; Yanlin Wei; Li Li; Qiuxia Li; Qing Lv; Jun Qi; Jianlin Huang; Tianwang Li; O Jin; Yunfeng Pan; J Gu
Journal:  Clin Rheumatol       Date:  2014-06-20       Impact factor: 2.980

10.  Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.

Authors:  Désirée M van der Heijde; Dennis A Revicki; Katherine L Gooch; Robert L Wong; Hartmut Kupper; Neesha Harnam; Chris Thompson; Joachim Sieper
Journal:  Arthritis Res Ther       Date:  2009-08-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.